- Exelixis (NASDAQ:EXEL): Q3 Non-GAAP EPS of $0.04 beats by $0.03; GAAP EPS of -$0.10 misses by $0.11.
- Revenue of $231.09M (-14.9% Y/Y) beats by $15.69M.
- “In the third quarter of 2020, the Exelixis team built the foundation to accelerate revenue growth with CABOMETYX® (cabozantinib) in 2021,” said Michael M. Morrissey, Ph.D., President and CEO.
- Press Release
- https://seekingalpha.com/news/3632449-exelixis-eps-beats-0_03-beats-on-revenue
Thursday, November 5, 2020
Exelixis EPS beats by $0.03, beats on revenue
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.